Current stock page

Financial Data

NAMS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

NAMSNewAmsterdam Pharma Company N.V.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$20.14+$0.17 (+0.85%)

Latest quote

  • Momentum
    22
  • Value
    42
  • Quality
    58
  • Risk resilience
    48
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$19.16M$3.7M$3.04M$32K$348K$19.15M$2.98M$12.77M
Gross Profit$19.16M$3.7M$2.54M-$27K$348K$19.15M$2.98M$12.77M
Operating Income-$44.19M-$64.86M-$58.42M-$65.98M-$55.14M-$35.64M-$68.93M-$43.23M
Net Income-$17.39M-$64.14M-$48.44M-$74.92M-$72.01M-$17.36M-$39.53M-$92.18M
EPS-$0.14-$0.52-$0.4-$0.65-$0.61-$0.15-$0.34-$0.98
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$39.77M-$39.21M-$30.6M-$40.88M-$32.77M-$37.67M-$36.47M-$37.48M
Capital Expenditure-$177K-$80K-$38K-$100K-$42K-$88K-$16K-$3K
Free Cash Flow-$39.95M-$39.29M-$30.64M-$40.98M-$32.81M-$37.76M-$36.48M-$37.48M
Net Cash Provided By Operating Activities-$39.77M-$39.21M-$30.6M-$40.88M-$32.77M-$37.67M-$36.47M-$37.48M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$687.99M$704.45M$732.64M$769.28M$786.43M$815.11M$818.41M$864.62M
Total Debt$76K$82K$23K$202K$266K$328K$389K$448K
Cash And Cash Equivalents$423.13M$424.15M$457.61M$490M$538.41M$563.86M$748.42M$771.74M
Total Liabilities$57.2M$73.03M$67.42M$85.85M$58.36M$36.62M$41.05M$107.12M
Total Stockholders Equity$630.78M$631.42M$665.22M$683.43M$728.07M$778.5M$777.36M$757.5M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.725.366.345.996.233.412.882.52
P/S ratio96.39———————
Debt To Equity00000000
Free Cash Flow Yield-6.43%-4.25%-3.37%-3.62%-3.19%-4.68%-6.29%-8.33%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.725.366.345.996.233.412.882.52
P/S ratio96.39———————
Return On Equity-32.48%-41.10%-31.98%-29.82%-30.36%-21.29%-24.10%-31.89%
Debt To Equity00000000

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-11.78x
Pb3.96x
Revenue Growth Yoy5406.90%
EPS Growth Yoy77.05%
Gross Margin97.84%
Operating Margin-900.07%
ROE-31.39%
ROIC-37.01%
Debt To Equity0
FCF Yield-6.25%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$20.14
Volume1.67M
RSI (14)47.28
MACD-0.57
MACD signal-0.72
MACD histogram0.14
ADX (14)16.73
SMA (50)$21.53
SMA (200)$29.16
ATR (14)$1.33
Historical volatility (annualized)69.83%
Volume (20-day average)1.76M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score48/100
Beta1.43
Annual volatility53.82%
Max Drawdown-54.43%
Sharpe Ratio-0.91
VaR (95%, 1-day)-5.23%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

NAMS Financial Data FAQ

What is NewAmsterdam Pharma Company N.V.'s revenue?

NewAmsterdam Pharma Company N.V.'s revenue is one of the core financial data points for NAMS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is NewAmsterdam Pharma Company N.V.'s revenue growing?

Revenue growth shows whether NewAmsterdam Pharma Company N.V. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is NAMS's EPS?

NAMS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is NewAmsterdam Pharma Company N.V.'s net income?

NewAmsterdam Pharma Company N.V.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does NewAmsterdam Pharma Company N.V. generate?

Free cash flow shows how much cash NewAmsterdam Pharma Company N.V. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does NewAmsterdam Pharma Company N.V. have?

Cash and debt help frame NAMS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.